| Q99636438 | A mouse brain-based multi-omics integrative approach reveals potential blood biomarkers for ischemic stroke |
| Q38557491 | A novel mechanism of neuroprotection: Blood glutamate grabber |
| Q53281779 | A panoramic, practice-based view of intravenous alteplase 3–4·5 h after stroke |
| Q48492472 | A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China |
| Q47406108 | Acute connexin43 temporal and spatial expression in response to ischemic stroke |
| Q28391839 | Age and the metabolic syndrome as risk factors for ischemic stroke: improving preclinical models of ischemic stroke |
| Q38040823 | Alteplase: a review of its use in the management of acute ischaemic stroke |
| Q38784698 | Amelioration of Ischemic Brain Injury in Rats With Human Umbilical Cord Blood Stem Cells: Mechanisms of Action. |
| Q37009832 | Aneurysmal subarachnoid hemorrhage models: do they need a fix? |
| Q36241295 | Angiographic and Clinical Factors Related with Good Functional Outcome after Mechanical Thrombectomy in Acute Cerebral Artery Occlusion |
| Q41314097 | Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke |
| Q34991506 | Augmenting collateral blood flow during ischemic stroke via transient aortic occlusion |
| Q64238872 | Biomarker for Ischemic Stroke Using Metabolome: A Clinician Perspective |
| Q33722600 | Bladder Transplantation of Amniotic Fluid Stem Cell may Ameliorate Bladder Dysfunction After Focal Cerebral Ischemia in Rat |
| Q38263335 | Cerebral collaterals and collateral therapeutics for acute ischemic stroke |
| Q61817311 | Combined proteomic and metabolomic analyses of cerebrospinal fluid from mice with ischemic stroke reveals the effects of a Buyang Huanwu decoction in neurodegenerative disease |
| Q34223485 | Construction, expression and refolding of a bifunctional fusion protein consisting of C-terminal 12-residue of hirudin-PA and reteplase |
| Q26853706 | Current understanding of TRPM7 pharmacology and drug development for stroke |
| Q53359412 | Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones. |
| Q48766826 | Determination of the therapeutic time window for human umbilical cord blood mononuclear cell transplantation following experimental stroke in rats. |
| Q38088270 | Development of transcranial sonothrombolysis as an alternative stroke therapy: incremental scientific advances toward overcoming substantial barriers |
| Q36841904 | Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules |
| Q87354559 | Efficacy of systemic thrombolysis within 4.5 h from stroke symptom onset: a single-centre clinical and diffusion-perfusion 3T MRI study |
| Q35955138 | Electroacupuncture Pretreatment as a Novel Avenue to Protect Brain against Ischemia and Reperfusion Injury |
| Q37715322 | Electroacupuncture-induced neuroprotection against focal cerebral ischemia in the rat is mediated by adenosine A1 receptors |
| Q35992243 | Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial |
| Q35029799 | Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims |
| Q53221658 | Etiology and treatment of ischaemic stroke in patients with β-thalassemia major. |
| Q34015457 | Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization |
| Q37420266 | Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. |
| Q59713142 | Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis |
| Q47862212 | Human Umbilical Cord Mesenchymal Stem Cells Preserve Adult Newborn Neurons and Reduce Neurological Injury after Cerebral Ischemia by Reducing the Number of Hypertrophic Microglia/Macrophages. |
| Q57173176 | Identification and functional analysis of differentially expressed genes associated with cerebral ischemia/reperfusion injury through bioinformatics methods |
| Q33926874 | Imaging and treatment of patients with acute stroke: an evidence-based review |
| Q48376566 | Imaging techniques for acute ischemic stroke: nice gadgets or essential tools for effective treatment? |
| Q37052689 | Impact of Protocol Deviations in Acute Ischemic Stroke Treated With Intravenous rt-PA Within 4.5 Hours After Symptom Onset |
| Q34006140 | Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence |
| Q37417581 | Implementation of Computerized Physician Order Entry Is Associated With Increased Thrombolytic Administration for Emergency Department Patients With Acute Ischemic Stroke. |
| Q97692853 | Improved collateral flow and reduced damage after remote ischemic perconditioning during distal middle cerebral artery occlusion in aged rats |
| Q57064396 | Integrated Histotripsy and Bubble Coalescence Transducer for Thrombolysis |
| Q36048610 | Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment. |
| Q33785353 | Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis |
| Q38131951 | Intravenous thrombolysis for acute ischemic stroke in the 3- to 4·5-hour window--the Malabar experience. |
| Q60221610 | Intérêt de la TDM de perfusion dans le diagnostic d’un AVC ischémique sylvien à la phase précoce |
| Q48641644 | Is point-of-care accurate for indicating thrombolysis in anticoagulated patients on oral anticoagulation treatments? |
| Q50025989 | Long-Term Survival After Intravenous Thrombolysis for Ischemic Stroke: A Propensity Score-Matched Cohort With up to 10-Year Follow-Up |
| Q37732255 | Mechanical thrombectomy for the treatment of acute ischemic stroke |
| Q47694508 | Mild acute ischaemic stroke--the case for thrombolytic therapy |
| Q38247178 | Modulation of brain plasticity in stroke: a novel model for neurorehabilitation |
| Q28550456 | Multiplex Brain Proteomic Analysis Revealed the Molecular Therapeutic Effects of Buyang Huanwu Decoction on Cerebral Ischemic Stroke Mice |
| Q35103426 | NAD+ depletion or PAR polymer formation: which plays the role of executioner in ischaemic cell death? |
| Q37877883 | Neural bases of recovery after brain injury |
| Q45419567 | Neurointerventional treatment in acute stroke. Whom to treat? (Endovascular treatment for acute stroke: utility of THRIVE score and HIAT score for patient selection). |
| Q37668019 | One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke |
| Q38019575 | Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA). |
| Q30739355 | Optogenetic Approaches to Target Specific Neural Circuits in Post-stroke Recovery |
| Q48166886 | Peroxynitrite Decomposition Catalyst Reduces Delayed Thrombolysis-induced Hemorrhagic Transformation in Ischemia-reperfused Rat Brains |
| Q57736120 | Poster Presentations |
| Q93108461 | Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels |
| Q35671209 | Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012. |
| Q35887325 | Prokineticin 2 is an endangering mediator of cerebral ischemic injury |
| Q37052686 | Quality measures in stroke |
| Q53186360 | Quantification of thrombus hounsfield units on noncontrast CT predicts stroke subtype and early recanalization after intravenous recombinant tissue plasminogen activator. |
| Q36816551 | RIGOR guidelines: escalating STAIR and STEPS for effective translational research |
| Q34540670 | Recanalization and Reperfusion Therapies of Acute Ischemic Stroke: What have We Learned, What are the Major Research Questions, and Where are We Headed? |
| Q34462146 | Recombinant tissue plasminogen activators (rtPA): a review |
| Q57808759 | Resveratrol Preconditioning Induces Genomic and Metabolic Adaptations within the Long-Term Window of Cerebral Ischemic Tolerance Leading to Bioenergetic Efficiency |
| Q36917400 | Safety and efficacy evaluation of carnosine, an endogenous neuroprotective agent for ischemic stroke |
| Q38075828 | Safety and efficacy of thrombolysis with intravenous alteplase in older stroke patients |
| Q37901770 | Shaping plasticity to enhance recovery after injury |
| Q36307742 | Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders. |
| Q33976397 | Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator |
| Q30642123 | Six-month ischemic mice show sensorimotor and cognitive deficits associated with brain atrophy and axonal disorganization |
| Q37150313 | Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke |
| Q37941678 | Standardized prehospital treatment of stroke |
| Q48426796 | Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial |
| Q35164861 | Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. |
| Q33734891 | Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science |
| Q52637945 | The 5α-Reductase Inhibitor Finasteride Exerts Neuroprotection Against Ischemic Brain Injury in Aged Male Rats. |
| Q38776049 | The High Cost of Stroke and Stroke Cytoprotection Research. |
| Q38661899 | The NAD+-Dependent Family of Sirtuins in Cerebral Ischemia and Preconditioning |
| Q37955226 | The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease |
| Q38764867 | Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke |
| Q42668646 | Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). |
| Q35552867 | Thrombolytic therapy for acute ischemic stroke beyond three hours |
| Q35213585 | Tissue plasminogen activator prevents white matter damage following stroke |
| Q37868574 | Translating promising preclinical neuroprotective therapies to human stroke trials |
| Q33896024 | Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development |
| Q48670485 | Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator |
| Q35109940 | Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients. |
| Q64081249 | Using Dental Pulp Stem Cells for Stroke Therapy |
| Q46133359 | Utilization of intravenous thrombolysis is increasing in the United States |
| Q53169230 | [Computerized tomography utilization for stroke inpatients in the Brazilian Health System]. |